Nothing Special   »   [go: up one dir, main page]

AR108179A2 - Compuestos de pirrolo[2,3-d]pirimidina y sus usos para el tratamiento de diversos tipos de cáncer por medio de la modulación de la actividad de la cinasa de proteína tirosina - Google Patents

Compuestos de pirrolo[2,3-d]pirimidina y sus usos para el tratamiento de diversos tipos de cáncer por medio de la modulación de la actividad de la cinasa de proteína tirosina

Info

Publication number
AR108179A2
AR108179A2 ARP170100874A ARP170100874A AR108179A2 AR 108179 A2 AR108179 A2 AR 108179A2 AR P170100874 A ARP170100874 A AR P170100874A AR P170100874 A ARP170100874 A AR P170100874A AR 108179 A2 AR108179 A2 AR 108179A2
Authority
AR
Argentina
Prior art keywords
substituted
alkyl
cycloalkyl
heterocyclyl
heteroaryl
Prior art date
Application number
ARP170100874A
Other languages
English (en)
Original Assignee
Novartis Ag
Astex Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38779335&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR108179(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag, Astex Therapeutics Ltd filed Critical Novartis Ag
Publication of AR108179A2 publication Critical patent/AR108179A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

La presente solicitud describe compuestos orgánicos que son útiles para el tratamiento, la prevención, y/o el alivio de enfermedades; en particular se describen compuestos de pirrolo-pirimidina y sus derivados, que inhiben a las cinasas de proteína. Los compuestos orgánicos son útiles en el tratamiento de enfermedades proliferativas. Reivindicación 1: Un compuesto de la fórmula (1), o una sal farmacéuticamente aceptable o solvato del mismo, caracterizado porque: la línea punteada indica un enlace doble; A es N o CR⁵, en donde R⁵ es hidrógeno o alquilo C₁₋₃; R² y R³ se seleccionan cada uno independientemente a partir del grupo que consiste en hidrógeno, hidroxilo, alquilo C₁₋₃, cicloalquilo C₃₋₈, heterociclilo, arilo, heteroarilo, alquilo C₁₋₃ sustituido, cicloalquilo C₃₋₈ sustituido, heterociclilo sustituido, arilo sustituido, y heteroarilo sustituido; R⁴ es seleccionado del grupo que consiste de C(H)(CH₂CH₃)₂, C(H)(CH₂CH₃)Ph, CH₂CH₃, ciclopropilo, ciclopentilo o ciclohexilo; X es N o CR¹¹, e Y es CR¹²; R¹¹ es seleccionado del grupo que consiste de halógeno, hidrógeno, alquilo C₁₋₃, alcoxi C₁₋₃, CN, C=NOH, C=NOCH₃, C(O)H, C(O)alquilo C₁₋₃, cicloalquilo C₃₋₈, heterociclilo, arilo, heteroarilo, alquilo C₁₋₃ substituido, cicloalquilo C₃₋₈ substituido, heterociclilo substituido, arilo substituido, heteroarilo substituido, -BNR¹³R¹⁴, -BOR¹³, -BC(O)R¹³, -BC(O)OR¹³, -BC(O)NR¹³R¹⁴; donde B es un enlace, alquilo C₁₋₃ o alquilo C₁₋₃ ramificado; donde R¹³ y R¹⁴ son cada uno, independientemente, seleccionados del grupo que consiste de hidrógeno, alquilo C₁₋₃, cicloalquilo C₃₋₈, heterociclilo, arilo, heteroarilo, alquilo substituido, cicloalquilo substituido, heterociclilo substituido, arilo substituido, y heteroarilo substituido y R¹² es -BC(O)NR¹³R¹⁴; donde B es un enlace, alquilo C₁₋₃ o alquilo C₁₋₃ ramificado; donde R¹³ y R¹⁴ son cada una, independientemente, seleccionados del grupo que consiste de hidrógeno, alquilo C₁₋₃, cicloalquilo C₃₋₈, heterociclilo, arilo, heteroarilo, alquilo substituido, cicloalquilo substituido, heterociclilo substituido, arilo substituido, y heteroarilo substituido.
ARP170100874A 2006-05-26 2017-04-05 Compuestos de pirrolo[2,3-d]pirimidina y sus usos para el tratamiento de diversos tipos de cáncer por medio de la modulación de la actividad de la cinasa de proteína tirosina AR108179A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US80860506P 2006-05-26 2006-05-26

Publications (1)

Publication Number Publication Date
AR108179A2 true AR108179A2 (es) 2018-07-25

Family

ID=38779335

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP070102252A AR061124A1 (es) 2006-05-26 2007-05-24 Compuestos de pirrolo[2, 3 - d]pirimidina y sus usos para el tratamiento de diversos tipos de cancer por medio de la modulacion de la actividad de la cinasa de proteina tirosina.
ARP170100874A AR108179A2 (es) 2006-05-26 2017-04-05 Compuestos de pirrolo[2,3-d]pirimidina y sus usos para el tratamiento de diversos tipos de cáncer por medio de la modulación de la actividad de la cinasa de proteína tirosina

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP070102252A AR061124A1 (es) 2006-05-26 2007-05-24 Compuestos de pirrolo[2, 3 - d]pirimidina y sus usos para el tratamiento de diversos tipos de cancer por medio de la modulacion de la actividad de la cinasa de proteina tirosina.

Country Status (38)

Country Link
US (2) US8324225B2 (es)
EP (1) EP2029145B1 (es)
JP (2) JP2009538341A (es)
KR (1) KR101466412B1 (es)
CN (1) CN101594871B (es)
AR (2) AR061124A1 (es)
AU (1) AU2007267645C1 (es)
BR (1) BRPI0712816B8 (es)
CA (1) CA2652044C (es)
CL (1) CL2007001504A1 (es)
CR (1) CR10433A (es)
CU (1) CU23831B1 (es)
EA (1) EA016301B1 (es)
EC (1) ECSP088910A (es)
ES (1) ES2623133T3 (es)
GE (1) GEP20115283B (es)
GT (1) GT200800258A (es)
HN (1) HN2008001752A (es)
HR (1) HRP20170631T1 (es)
IL (1) IL195086A (es)
JO (1) JO3235B1 (es)
MA (1) MA30557B1 (es)
ME (1) ME00486B (es)
MX (1) MX2008015076A (es)
MY (1) MY150650A (es)
NO (1) NO343182B1 (es)
NZ (1) NZ572549A (es)
PE (1) PE20080263A1 (es)
PL (1) PL2029145T3 (es)
PT (1) PT2029145T (es)
SG (1) SG172632A1 (es)
SM (1) SMP200800069B (es)
TN (1) TNSN08481A1 (es)
TW (1) TWI398252B (es)
UA (1) UA95632C2 (es)
UY (1) UY30369A1 (es)
WO (1) WO2007140222A2 (es)
ZA (1) ZA200809382B (es)

Families Citing this family (181)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2348023E (pt) 2005-12-13 2015-09-15 Incyte Corp Pirrolo[2,3-b] pirimidinas e pirrolo[2,3-b]piridinas substituídas com heteroarilo como inibidores de janus quinase
US7989459B2 (en) 2006-02-17 2011-08-02 Pharmacopeia, Llc Purinones and 1H-imidazopyridinones as PKC-theta inhibitors
CL2007002866A1 (es) 2006-10-04 2008-07-04 Pharmacopeia Inc Compuestos derivados de 6-sustituidos-2-(bencimidazolil) purina y purinona; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de enfermedades autoinmunes, enfermedad inflamatoria, enfermedad mediada por m
CL2007002867A1 (es) 2006-10-04 2008-06-27 Pharmacopeia Inc Compuestos derivados de 2-(bencimidazolil)purina, inhibidores de janus quinasa 3; composicion farmaceutica que los contiene; y su uso para tratar enfermedades autoinmune, inflamatorias, cardiovasculares, rechazo de implante, entre otras.
US7902187B2 (en) 2006-10-04 2011-03-08 Wyeth Llc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
SG182198A1 (en) 2007-06-13 2012-07-30 Incyte Corp Salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
MX2010002115A (es) * 2007-08-23 2010-06-01 Aztrazeneca Ab 2-anilinopurin-8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos .proliferativos.
AU2008343932B2 (en) 2007-12-19 2013-08-15 Amgen Inc. Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
CN101981036B (zh) 2008-02-06 2013-09-04 诺瓦提斯公司 吡咯并[2,3-d]嘧啶及其作为酪氨酸激酶抑制剂的用途
TW200942544A (en) * 2008-03-03 2009-10-16 Takeda Pharmaceutical Combination drug
WO2009126584A1 (en) * 2008-04-07 2009-10-15 Amgen Inc. Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors
TW201002713A (en) * 2008-04-09 2010-01-16 Organon Nv Pyrrolo[2,3-d]pyrimidin-2-yl-amine derivatives as PKC-theta inhibitors
US8748469B2 (en) 2008-04-24 2014-06-10 Newlink Genetics Corporation IDO inhibitors
WO2009152027A1 (en) * 2008-06-12 2009-12-17 Merck & Co., Inc. 5,7-dihydro-6h-pyrrolo[2,3-d]pyrimidin-6-one derivatives for mark inhibition
KR101353857B1 (ko) * 2008-08-22 2014-01-21 노파르티스 아게 Ｃｄｋ 억제제로서 피롤로피리미딘 화합물
WO2010045451A1 (en) * 2008-10-16 2010-04-22 Glaxosmithkline Llc Pyrrolopyrimidine compounds
GB0903759D0 (en) * 2009-03-04 2009-04-15 Medical Res Council Compound
AU2010248886A1 (en) 2009-05-13 2011-12-01 The University Of North Carolina At Chapel Hill Cyclin dependent kinase inhibitors and methods of use
WO2010135650A1 (en) 2009-05-22 2010-11-25 Incyte Corporation N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS
PE20120371A1 (es) 2009-05-22 2012-05-17 Incyte Corp 3-[4-(7h-pirrolo[2,3-d]pirimidin-4il)-1h-pirazol-1-il]octano o heptano-nitrilo como inhibidores de jak
WO2011028685A1 (en) 2009-09-01 2011-03-10 Incyte Corporation Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
TWI478714B (zh) 2009-10-29 2015-04-01 Vectura Ltd 作為Ｊａｎｕｓ激酶３（ＪＡＫ３）抑制劑之含氮雜芳基衍生物類
US20130022629A1 (en) * 2010-01-04 2013-01-24 Sharpe Arlene H Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof
ES2730763T3 (es) 2010-02-11 2019-11-12 Celgene Corp Derivados de arilmetoxi isoindolina y composiciones que los comprenden y métodos de uso de los mismos
UY33227A (es) * 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
UY33226A (es) * 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6
TWI531572B (zh) 2010-03-10 2016-05-01 英塞特公司 作為ｊａｋ１抑制劑之哌啶－４－基三亞甲亞胺衍生物
KR101830455B1 (ko) * 2010-04-13 2018-02-20 노파르티스 아게 시클린 의존성 키나제 ４ 또는 시클린 의존성 키나제 （ｃｄｋ４／６） 억제제 및 ｍｔｏｒ 억제제를 포함하는 암 치료를 위한 조합물
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
WO2011146313A1 (en) 2010-05-19 2011-11-24 The University Of North Carolina At Chapel Hill Pyrazolopyrimidine compounds for the treatment of cancer
RS54824B1 (sr) 2010-05-21 2016-10-31 Incyte Holdings Corp Topikalna formulacija za inhibiciju jak-a
EP3567042B1 (en) * 2010-10-25 2021-07-07 G1 Therapeutics, Inc. Cdk inhibitors
AR083797A1 (es) * 2010-11-10 2013-03-20 Novartis Ag Succinato de dimetil-amida del acido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-[2,3-d]pirimidin-6-carboxilico, proceso para prepararla, intermediarios de dicha sintesis y proceso de preparacion de los mismos
CA2818046A1 (en) 2010-11-17 2012-05-24 The University Of North Carolina At Chapel Hill Protection of renal tissues from ischemia through inhibition of the proliferative kinases cdk4 and cdk6
JP5917544B2 (ja) 2010-11-19 2016-05-18 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｊａｋ阻害剤としての複素環置換ピロロピリジンおよびピロロピリミジン
CA2818542A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
CN102093364B (zh) * 2011-01-07 2015-01-28 北京赛林泰医药技术有限公司 作为FAK/Pyk2抑制剂的2,4-二氨基-6,7-二氢-5H-吡咯并[2,3]嘧啶衍生物
CN103476776B (zh) * 2011-01-07 2016-09-28 北京赛林泰医药技术有限公司 作为FAK/Pyk2抑制剂的2,4-二氨基-6,7-二氢-5H-吡咯并[2,3]嘧啶衍生物
CN103534241B (zh) 2011-02-17 2015-11-25 癌症疗法Crc私人有限公司 Fak抑制剂
ES2724525T3 (es) 2011-02-17 2019-09-11 Cancer Therapeutics Crc Pty Ltd Inhibidores selectivos de FAK
GB201104267D0 (en) 2011-03-14 2011-04-27 Cancer Rec Tech Ltd Pyrrolopyridineamino derivatives
BR112013024267A2 (pt) 2011-03-22 2018-06-26 Advinus Therapeutics Ltd compostos tricíclicos fundidos substituídos, composições e aplicações medicinais dos mesmos.
EP2937349B1 (en) 2011-03-23 2016-12-28 Amgen Inc. Fused tricyclic dual inhibitors of cdk 4/6 and flt3
CA2836417A1 (en) * 2011-05-17 2012-11-22 Principia Biopharma Inc. Azaindole derivatives as tyrosine kinase inhibitors
CA2839767A1 (en) 2011-06-20 2012-12-27 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
EP2726076B1 (en) 2011-07-01 2016-10-12 Novartis AG Combination therapy
BR112013033940A2 (pt) 2011-07-01 2017-02-14 Novartis Ag terapia combinada compreendendo um inibidor de cdk4/6 e um inibidor de pi3k para uso no tratamento de câncer
US9233111B2 (en) 2011-07-08 2016-01-12 Novartis Ag Pyrrolo pyrimidine derivatives
WO2013017480A1 (en) * 2011-07-29 2013-02-07 Cellzome Limited Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors
WO2013017479A1 (en) * 2011-07-29 2013-02-07 Cellzome Limited Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
RU2631655C2 (ru) 2011-10-03 2017-09-26 Зэ Юниверсити Оф Норд Каролина Эт Чапель Хилл Пирролопиримидиновые соединения для лечения злокачественной опухоли
US9498471B2 (en) 2011-10-20 2016-11-22 The Regents Of The University Of California Use of CDK9 inhibitors to reduce cartilage degradation
WO2013173720A1 (en) 2012-05-18 2013-11-21 Incyte Corporation Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
AU2013266438B2 (en) 2012-05-22 2017-09-07 The University Of North Carolina At Chapel Hill Pyrimidine compounds for the treatment of cancer
EA201492104A1 (ru) * 2012-06-14 2015-06-30 Эли Лилли Энд Компани Ингибитор jak1/2
US8673972B2 (en) 2012-08-03 2014-03-18 Foundation Medicine, Inc. Human papilloma virus as predictor of cancer prognosis
GB201216018D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Pharmacologically active compounds
GB201216017D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Inhibitor compounds
IN2015DN02008A (es) 2012-09-21 2015-08-14 Advinus Therapeutics Ltd
JP2015531395A (ja) 2012-10-04 2015-11-02 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ ピロロ［３，２−ｃ］ピリジントロポミオシン関連キナーゼ阻害剤
US9562047B2 (en) 2012-10-17 2017-02-07 The University Of North Carolina At Chapel Hill Pyrazolopyrimidine compounds for the treatment of cancer
AU2013344780B2 (en) 2012-11-15 2018-03-01 Incyte Holdings Corporation Sustained-release dosage forms of ruxolitinib
EP2925752A4 (en) 2012-11-27 2016-06-01 Univ North Carolina PYRIMIDINE COMPOUNDS FOR CANCER TREATMENT
EP2742940B1 (en) 2012-12-13 2017-07-26 IP Gesellschaft für Management mbH Fumarate salt of (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-l-aza-bicyclo-[2.2.2]octane for adminstration once daily, twice daily or thrice daily
EP2934515B1 (en) * 2012-12-20 2018-04-04 Novartis AG A pharmaceutical combination comprising binimetinib
US9708326B2 (en) 2013-02-25 2017-07-18 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
JP2016516005A (ja) 2013-02-25 2016-06-02 ノバルティス アーゲー 新規のアンドロゲンレセプター変異
EP2964648B1 (en) * 2013-03-05 2016-11-16 Merck Patent GmbH 9-(aryl or heteroaryl)-2-(pyrazolyl, pyrrolidinyl or cyclopentyl)aminopurine derivatives as anticancer agents
US8987443B2 (en) 2013-03-06 2015-03-24 Incyte Corporation Processes and intermediates for making a JAK inhibitor
SG10201906270VA (en) 2013-03-21 2019-08-27 Novartis Ag Combination therapy comprising a b-raf inhibitor and a second inhibitor
EP2986740B1 (en) 2013-04-16 2020-01-15 Memorial Sloan-Kettering Cancer Center Companion diagnostic for cdk4 inhibitors
BR112015025260B1 (pt) 2013-04-25 2021-11-03 Beigene, Ltd Compostos heterocíclicos fundidos como inibidores da proteína quinase, sua composição, combinação e uso
US8895611B1 (en) 2013-07-17 2014-11-25 King Fahd University Of Petroleum And Minerals Cytotoxic compounds for treating cancer
CN105579032A (zh) 2013-08-07 2016-05-11 因赛特公司 Jak1抑制剂的持续释放剂型
CN103408546A (zh) * 2013-08-22 2013-11-27 中国药科大学 2-苯氨基嘌呤类plk1抑制剂及其用途
DK3044234T3 (da) 2013-09-13 2020-05-18 Beigene Switzerland Gmbh Anti-PD1-antistoffer og anvendelse deraf som terapeutika og diagnostika
GB201403536D0 (en) 2014-02-28 2014-04-16 Cancer Rec Tech Ltd Inhibitor compounds
EP3122359B1 (en) 2014-03-26 2020-12-16 Astex Therapeutics Ltd. Combinations of an fgfr inhibitor and an igf1r inhibitor
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
CA2943682C (en) 2014-03-26 2024-02-13 Astex Therapeutics Ltd Combinations of fgfr and cmet inhibitors and their use for the treatmentof cancer
AU2015244171A1 (en) 2014-04-11 2016-11-03 The University Of North Carolina At Chapel Hill MerTK-specific pyrimidine compounds
WO2015160986A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
EP3148532B1 (en) 2014-05-28 2021-03-03 Piramal Enterprises Limited Pharmaceutical combination comprising a cdk inhibitor and a thioredoxin reductase inhibitor for the treatment of cancer
MX2016015565A (es) * 2014-05-28 2017-07-04 Shanghai Fochon Pharmaceutical Co Ltd Ciertos inhibidores de la proteina quinasa.
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
KR102003754B1 (ko) 2014-07-03 2019-07-25 베이진 엘티디 Pd-l1 항체와 이를 이용한 치료 및 진단
SG10202004716RA (en) 2014-07-24 2020-06-29 Beta Pharma Inc 2-h-indazole derivatives as cyclin-dependent kinase (cdk) inhibitors and therapeutic uses thereof
SG11201702759XA (en) 2014-10-06 2017-05-30 Signal Pharm Llc Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
AU2015333689A1 (en) 2014-10-14 2017-05-25 The Regents Of The University Of California Use of CDK9 and BRD4 inhibitors to inhibit inflammation
CN105111215B (zh) * 2014-12-12 2019-06-18 苏州晶云药物科技股份有限公司 一种周期蛋白依赖性激酶抑制剂的晶型及其制备方法
CN104610265A (zh) * 2014-12-31 2015-05-13 芜湖杨燕制药有限公司 一种化合物及其制备方法
CN104606197A (zh) * 2014-12-31 2015-05-13 芜湖杨燕制药有限公司 一种化合物的抗肿瘤用途
JOP20200201A1 (ar) 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
AU2016219102B2 (en) * 2015-02-13 2020-10-15 Dana-Farber Cancer Institute, Inc. LRRK2 inhibitors and methods of making and using the same
CN106146515B (zh) * 2015-04-17 2020-09-04 常州隆赛医药科技有限公司 新型激酶抑制剂的制备及应用
MX2018003563A (es) 2015-09-23 2018-06-18 Janssen Pharmaceutica Nv Nuevos compuestos.
EP3353164B1 (en) 2015-09-23 2021-11-03 Janssen Pharmaceutica, N.V. Bi-heteroaryl substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer
CN108779117B (zh) * 2015-12-27 2021-08-31 重庆复创医药研究有限公司 一类激酶抑制剂
US10662186B2 (en) 2015-12-31 2020-05-26 Shanghai Pharmaceuticals Holding Co., Ltd. Substituted pyrimidines as cyclin-dependent kinase inhibitors
WO2017156263A1 (en) 2016-03-09 2017-09-14 Memorial Sloan-Kettering Cancer Center Enigma and cdh18 as companion diagnostics for cdk4 inhibitors
US10709708B2 (en) 2016-03-17 2020-07-14 The University Of North Carolina At Chapel Hill Method of treating cancer with a combination of MER tyrosine kinase inhibitor and an epidermal growth factor receptor (EGFR) inhibitor
PT3436019T (pt) 2016-04-01 2021-11-04 Signal Pharm Llc (1s,4s)-4-(2-(((3s,4r)-3-fluorotetra-hidro-2h-piran-4- il)amino)-8-((2,4,6-triclorofenil)amino)-9h-purin-9-il)-1- metilciclo-hexano-1-carboxamida e métodos de utilização dos mesmos
JP7014731B2 (ja) 2016-04-01 2022-02-01 シグナル ファーマシューティカルズ，エルエルシー 置換アミノプリン化合物、その組成物、及びそれらを用いた治療方法
US10864203B2 (en) 2016-07-05 2020-12-15 Beigene, Ltd. Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer
CN116478166A (zh) 2016-08-16 2023-07-25 百济神州(苏州)生物科技有限公司 一种化合物的晶型、其制备和用途
CN118252927A (zh) 2016-08-19 2024-06-28 百济神州有限公司 使用包含btk抑制剂的组合产品治疗癌症
AU2017315357B2 (en) 2016-08-23 2022-12-01 Eisai R&D Management Co., Ltd. Combination therapies for the treatment of hepatocellular carcinoma
MA46285A (fr) 2016-09-19 2019-07-31 Mei Pharma Inc Polythérapie
BR112019005526A2 (pt) 2016-10-20 2019-06-18 Pfizer agentes antiproliferativos para tratamento de pah
WO2018081211A1 (en) * 2016-10-26 2018-05-03 Li George Y Deuterated 7-cyclopentyl-n, n-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7h-pyrrolo[2,3-d]pyrimdine-6-carboxamide
WO2018094227A1 (en) 2016-11-17 2018-05-24 The University Of North Carolina At Chapel Hill Alkyl pyrrolopyrimidine analogs and methods of making and using same
KR102220971B1 (ko) 2016-12-20 2021-02-25 아스트라제네카 아베 아미노-트리아졸로피리딘 화합물 및 암 치료에서의 이의 용도
WO2018117177A1 (ja) * 2016-12-21 2018-06-28 小野薬品工業株式会社 Ｂｒｋ阻害化合物
US10954216B2 (en) 2016-12-27 2021-03-23 Riken BMP-signal-inhibiting compound
US11555038B2 (en) 2017-01-25 2023-01-17 Beigene, Ltd. Crystalline forms of (S)-7-(1-(but-2-ynoyl)piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
JP7142846B2 (ja) * 2017-01-30 2022-09-28 国立大学法人京都大学 新規化合物及び制御性ｔ細胞の製造方法
MA47776A (fr) 2017-03-16 2020-01-22 Eisai R&D Man Co Ltd Polythérapies pour le traitement du cancer du sein
WO2018218633A1 (en) 2017-06-02 2018-12-06 Beijing Percans Oncology Co. Ltd. Combination therapies for treating cancers
WO2018232235A1 (en) 2017-06-16 2018-12-20 Beta Pharma, Inc. Pharmaceutical formulations of n-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and salts thereof
GB201709840D0 (en) 2017-06-20 2017-08-02 Inst Of Cancer Research: Royal Cancer Hospital Methods and medical uses
AU2018290532A1 (en) 2017-06-26 2019-11-21 Beigene, Ltd. Immunotherapy for hepatocellular carcinoma
CN110997677A (zh) 2017-08-12 2020-04-10 百济神州有限公司 具有改进的双重选择性的Btk抑制剂
WO2019062329A1 (zh) * 2017-09-28 2019-04-04 上海海雁医药科技有限公司 4,6,7-三取代1,2-二氢吡咯并[3,4-c]吡啶/嘧啶-3-酮衍生物及用途
WO2019070827A1 (en) 2017-10-04 2019-04-11 Celgene Corporation PROCESSES FOR THE PREPARATION OF CIS-4 [2 - {(3S, 4R) -3-FLUOROOXAN-4-YL] AMINO) -8- (2,4,6-TRICHLOROANILINO) -9H-PURIN-9-YL] -1 -MÉTHYLCYCLOHEXANE-1-carboxamide
CA3078368A1 (en) 2017-10-04 2019-04-11 Celgene Corporation Compositions and methods of use of cis-4-[2-{[(3s,4r)-3-fluorooxan-4-yl]amino}-8-(2,4,6-trichloroanilino)-9h-purin-9-yl]-1-methylcyclohexane-1-carboxamide
CN111801334B (zh) 2017-11-29 2023-06-09 百济神州瑞士有限责任公司 使用包含btk抑制剂的组合治疗惰性或侵袭性b-细胞淋巴瘤
AR113922A1 (es) 2017-12-08 2020-07-01 Incyte Corp Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
BR112020015405A2 (pt) 2018-01-29 2020-12-08 Beta Pharma, Inc. Compostos de 2h-indazóis como inibidores cdk4 e cdk6, composições farmacêuticas que os compreendem, seus usos terapêuticos e métodos de preparação
SI3746429T1 (sl) 2018-01-30 2023-01-31 Incyte Corporation Postopki za pripravo (1-(3-fluoro-2-(trifluorometil)izonikotinil) piperidin-4-ona)
JP7348665B2 (ja) 2018-02-06 2023-09-21 ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティ オブ イリノイ 選択的エストロゲン受容体分解剤としての置換ベンゾチオフェン類似体
CN113768927A (zh) 2018-03-30 2021-12-10 因赛特公司 使用jak抑制剂治疗化脓性汗腺炎
WO2019195959A1 (en) 2018-04-08 2019-10-17 Cothera Biosciences, Inc. Combination therapy for cancers with braf mutation
US10723739B2 (en) 2018-05-14 2020-07-28 Apotex Inc. Processes for the preparation of Ribociclib and intermediates thereof
WO2019222524A1 (en) * 2018-05-16 2019-11-21 The University Of North Carolina At Chapel Hill Alkyl pyrrolopyrimidines as pan-tam inhibitors and their application in cancer treatment
CN110577524B (zh) * 2018-06-07 2022-01-28 北京大学深圳研究生院 一种激酶选择性抑制剂
CN109438447B (zh) * 2018-09-11 2020-10-16 北京工业大学 5,7-二氢-6H-吡咯并[2,3-d]嘧啶-6-酮类衍生物制备方法和应用
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
EP3902805A4 (en) * 2018-12-28 2023-03-01 SPV Therapeutics Inc. CYCLIN DEPENDENT KINASE INHIBITORS
US20220056037A1 (en) * 2018-12-28 2022-02-24 Spv Therapeutics Inc. Cyclin-dependent kinase inhibitors
US11384083B2 (en) 2019-02-15 2022-07-12 Incyte Corporation Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
US11472791B2 (en) 2019-03-05 2022-10-18 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors
WO2020205560A1 (en) * 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
US11440914B2 (en) 2019-05-01 2022-09-13 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
WO2020223558A1 (en) 2019-05-01 2020-11-05 Incyte Corporation Tricyclic amine compounds as cdk2 inhibitors
US11136329B2 (en) 2019-05-08 2021-10-05 Vimalan Biosciences, Inc. JAK inhibitors
JOP20210298A1 (ar) 2019-05-14 2023-01-30 Provention Bio Inc طرق وتركيبات للوقاية من مرض السكري من النوع الأول
TW202110849A (zh) * 2019-05-27 2021-03-16 大陸商迪哲（江蘇）醫藥股份有限公司 Ｄｎａ依賴性蛋白激酶抑制劑
CN110305140B (zh) * 2019-07-30 2020-08-04 上海勋和医药科技有限公司 二氢吡咯并嘧啶类选择性jak2抑制剂
US11459333B2 (en) * 2019-08-08 2022-10-04 Vimalan Biosciences, Inc. Substituted pyrrolo[2,3-d]pyrimidines as JAK inhibitors
BR112022002698A2 (pt) 2019-08-14 2022-07-19 Incyte Corp Compostos de imidazolil pirimidinilamina como inibidores de cdk2
GB201911868D0 (en) * 2019-08-19 2019-10-02 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
BR112022005608A2 (pt) * 2019-09-25 2022-09-06 Vimalan Biosciences Inc Inibidores de jak
AU2020364007A1 (en) 2019-10-11 2022-04-28 Incyte Corporation Bicyclic amines as CDK2 inhibitors
US20240190861A1 (en) * 2019-10-17 2024-06-13 Cisen Pharmaceutical Co., Ltd Aminopyrimidine compound as cdk2/4/6 triple inhibitor
US20230357248A1 (en) * 2019-11-13 2023-11-09 Medshine Discovery Inc. Pyrrolopyrimidine compound as btk inhibitor and use thereof
KR20220113985A (ko) * 2019-12-16 2022-08-17 루넬라 바이오테크 인코포레이티드 선택적 cdk 4/6 억제제 암 치료제
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
IL298999A (en) 2020-06-11 2023-02-01 Provention Bio Inc Methods and compositions for the prevention of type 1 diabetes
WO2021257863A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Pyrrolotriazine compounds as jak2 v617f inhibitors
US11691971B2 (en) 2020-06-19 2023-07-04 Incyte Corporation Naphthyridinone compounds as JAK2 V617F inhibitors
KR102409595B1 (ko) * 2020-06-29 2022-06-17 한국과학기술연구원 단백질 카이네이즈 csf-1r 억제제로서의 신규 퓨리논 유도체
US11767323B2 (en) 2020-07-02 2023-09-26 Incyte Corporation Tricyclic pyridone compounds as JAK2 V617F inhibitors
IL299612A (en) 2020-07-02 2023-03-01 Incyte Corp Tricyclic urea compounds as JAK2 V617F inhibitors
US11661422B2 (en) 2020-08-27 2023-05-30 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
CZ309356B6 (cs) * 2020-09-15 2022-09-28 Ústav experimentální botaniky AV ČR, v. v. i Substituované purinové sloučeniny jako inhibitory proteinkináz, jejich použití jako léčiva a farmaceutické přípravky obsahující tyto deriváty
CN112375081B (zh) * 2020-11-23 2022-04-12 中国医学科学院医药生物技术研究所 具有抑制CDK4、6或9活性的吡咯[2,3-d]嘧啶衍生物及其制备方法和应用
WO2022140231A1 (en) * 2020-12-21 2022-06-30 Incyte Corporation Deazaguaine compounds as jak2 v617f inhibitors
WO2022135360A1 (zh) * 2020-12-21 2022-06-30 江苏恒瑞医药股份有限公司 嘌呤酮衍生物、其制备方法及其在医药上的应用
WO2022182839A1 (en) 2021-02-25 2022-09-01 Incyte Corporation Spirocyclic lactams as jak2 v617f inhibitors
EP4313987A2 (en) 2021-04-01 2024-02-07 KRKA, d.d., Novo mesto Process for the preparation of ribociclib and pharmaceutically acceptable salts thereof
WO2022226290A1 (en) * 2021-04-22 2022-10-27 H. Lee Moffitt Cancer Center And Research Institute, Inc. 2-phenylamino pyrrolopyrimidines as ack1 inhibitors
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
EP4367112A1 (en) 2021-07-09 2024-05-15 Plexium, Inc. Aryl compounds and pharmaceutical compositions that modulate ikzf2
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
IL315647A (en) 2022-03-17 2024-11-01 Incyte Corp Tricyclic urea compounds as Jak2 and 617f inhibitors
US11786531B1 (en) 2022-06-08 2023-10-17 Beigene Switzerland Gmbh Methods of treating B-cell proliferative disorder
WO2023241620A1 (en) * 2022-06-14 2023-12-21 Suzhou Keen Therapeutics Co., Ltd. Biologically active compounds and methods thereof
WO2024049926A1 (en) 2022-08-31 2024-03-07 Arvinas Operations, Inc. Dosage regimens of estrogen receptor degraders
WO2024056090A1 (zh) * 2022-09-16 2024-03-21 华东师范大学 作为rsk抑制剂的吡咯并嘧啶衍生物及其应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05306226A (ja) * 1992-04-27 1993-11-19 Takeda Chem Ind Ltd 慢性免疫疾患治療剤
RU2301233C2 (ru) 2002-03-07 2007-06-20 Ф.Хоффманн-Ля Рош Аг Бициклические пиридины и пиримидины в качестве ингибиторов киназы р38
CA2537829A1 (en) 2003-09-05 2005-03-17 Neurogen Corporation Heteroaryl fused pyridines, pyrazines and pyrimidines as crf1 receptor ligands
JP4895811B2 (ja) 2003-09-11 2012-03-14 ケミア，インコーポレイテッド サイトカイン阻害剤
US7319102B1 (en) * 2003-12-09 2008-01-15 The Procter & Gamble Company Pyrrolo[2,3-d]pyrimidine cytokine inhibitors
AU2005214352B2 (en) * 2004-02-14 2009-11-12 Irm Llc Compounds and compositions as protein kinase inhibitors
WO2005085253A1 (en) 2004-03-05 2005-09-15 Taisho Pharmaceutical Co., Ltd. Pyrrolopyrimidine derivatives
WO2005107760A1 (en) 2004-04-30 2005-11-17 Irm Llc Compounds and compositions as inducers of keratinocyte differentiation
US7906528B2 (en) 2004-10-05 2011-03-15 Novartis International Pharmaceutical Ltd. Pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds
MX2007005159A (es) * 2004-10-29 2007-06-26 Tibotec Pharm Ltd Derivados de pirimidina biciclicos inhibidores del vih.
US7723340B2 (en) * 2005-01-13 2010-05-25 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
US7521446B2 (en) 2005-01-13 2009-04-21 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
US7947695B2 (en) * 2005-01-14 2011-05-24 Janssen Pharmaceutica Nv 5-membered annelated heterocyclic pyrimidines as kinase inhibitors
WO2006091737A1 (en) 2005-02-24 2006-08-31 Kemia, Inc. Modulators of gsk-3 activity
JP2006241089A (ja) * 2005-03-04 2006-09-14 Astellas Pharma Inc ピロロピリミジン誘導体またはその塩
US20070225304A1 (en) * 2005-09-06 2007-09-27 Pharmacopeia Drug Discovery, Inc. Aminopurine derivatives for treating neurodegenerative diseases
GB0520164D0 (en) 2005-10-04 2005-11-09 Novartis Ag Organic compounds
WO2007058990A2 (en) * 2005-11-14 2007-05-24 Kemia, Inc. Therapy using cytokine inhibitors
GB0526246D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
JP2009529541A (ja) 2006-03-09 2009-08-20 ファーマコピア インコーポレーテッド 代謝性障害治療のための８−ヘテロアリ−ルプリンのｍｎｋ２阻害剤
US7998978B2 (en) 2006-05-01 2011-08-16 Pfizer Inc. Substituted 2-amino-fused heterocyclic compounds
CN101981036B (zh) 2008-02-06 2013-09-04 诺瓦提斯公司 吡咯并[2,3-d]嘧啶及其作为酪氨酸激酶抑制剂的用途

Also Published As

Publication number Publication date
KR101466412B1 (ko) 2014-11-28
AU2007267645A1 (en) 2007-12-06
BRPI0712816B8 (pt) 2021-05-25
AU2007267645B2 (en) 2011-09-01
IL195086A (en) 2015-10-29
EP2029145A2 (en) 2009-03-04
JO3235B1 (ar) 2018-03-08
IL195086A0 (en) 2009-08-03
ECSP088910A (es) 2008-12-30
PT2029145T (pt) 2017-04-24
MX2008015076A (es) 2009-03-05
TNSN08481A1 (en) 2010-04-14
TW200815011A (en) 2008-04-01
ZA200809382B (en) 2009-12-30
SMP200800069B (it) 2009-11-06
SG172632A1 (en) 2011-07-28
UY30369A1 (es) 2008-01-02
UA95632C2 (en) 2011-08-25
WO2007140222A2 (en) 2007-12-06
EP2029145B1 (en) 2017-01-25
BRPI0712816A2 (pt) 2012-10-23
CA2652044A1 (en) 2007-12-06
ES2623133T3 (es) 2017-07-10
NO343182B1 (no) 2018-11-26
MY150650A (en) 2014-02-14
PE20080263A1 (es) 2008-05-12
KR20090014219A (ko) 2009-02-06
CN101594871B (zh) 2013-06-19
JP2013091665A (ja) 2013-05-16
PL2029145T3 (pl) 2017-08-31
CU20080223A7 (es) 2010-07-20
WO2007140222A3 (en) 2008-08-07
CL2007001504A1 (es) 2008-05-09
HRP20170631T1 (hr) 2017-08-11
TWI398252B (zh) 2013-06-11
CN101594871A (zh) 2009-12-02
NO20085030L (no) 2009-01-06
BRPI0712816B1 (pt) 2021-01-19
JP2009538341A (ja) 2009-11-05
CU23831B1 (es) 2012-10-15
AR061124A1 (es) 2008-08-06
GEP20115283B (en) 2011-09-12
GT200800258A (es) 2009-06-24
AU2007267645C1 (en) 2012-07-12
CA2652044C (en) 2016-01-12
US20120207763A1 (en) 2012-08-16
MA30557B1 (fr) 2009-07-01
US20090318441A1 (en) 2009-12-24
HN2008001752A (es) 2011-07-12
CR10433A (es) 2009-01-15
EA016301B1 (ru) 2012-04-30
JP5740417B2 (ja) 2015-06-24
SMAP200800069A (it) 2008-12-23
NZ572549A (en) 2011-10-28
US8324225B2 (en) 2012-12-04
ME00486B (me) 2011-10-10
EA200802332A1 (ru) 2009-06-30

Similar Documents

Publication Publication Date Title
AR108179A2 (es) Compuestos de pirrolo[2,3-d]pirimidina y sus usos para el tratamiento de diversos tipos de cáncer por medio de la modulación de la actividad de la cinasa de proteína tirosina
AR111763A2 (es) Compuestos de pirrolo-pirimidina y sus usos
CR11650A (es) DERIVADOS BICICLICOS HETEROCICLICOS O ESPIROBICICLICOS HETEROCICLICOS ENLAZADOS, DE PIRAZOLO[1,5-a] PIRIMIDINAS, PROCEDIMIENTOS PARA SU PREPARACION Y USOS DE LOS MISMOS
AR071873A1 (es) Sales de 2-fluoro-n-metil-4-[7-(quinolin-6-il-metil)-imidazo[1,2-b][1,2,4]triazin-2-il]benzamida, un hidrato de la sal, un metodo de preparacion del compuesto, una composicion que lo comprende, un metodo para inhibir la actividad de la tirosina quinasa, un metodo para tratar una enfermedad y un proc
DOP2018000187A (es) Derivados de pirazolo[1,5-a]pirazin-4-ilo
GT200500242A (es) Procesos para la preparaciòn de 2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolinas sustituidas
ECSP109953A (es) Derivados de piridazinona
UY32302A (es) Carboxamidas heterobicíclicas como inhibidoras de cinasas
CO2017004481A2 (es) Compuestos de indol carboxamida utiles como inhibidores de cinasas
NI201000050A (es) Derivados de pirrolo [2, 3-d] pirimidina como inhibidores de proteínas quinasas b.
NI201000145A (es) DERIVADOS DE IMIDAZO - [1, 2-b] - PIRIDAZINA PARA EL TRATAMIENTO DE ENFERMEDAD MEDIADA POR CINASA DE TIROSINA C-MET.
GT200500103A (es) 4-fenilamino-quinazolin-6-il-amidas
UY34451A (es) Derivados de uracilo como inhibidores de la quinasa axl y c-met
PE20190811A1 (es) Derivados de pirazolopirimidinas como inhibidor de quinasa
NI201800033A (es) Derivados de 8-[6-[3-(amino)propoxi]-3piridil]-1-isopropil-imidazo[4, 5-c]quinolin -2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) para el tratamiento del cáncer.
CR11201A (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas
EA201491592A1 (ru) Соединения индолов и индазолов, активирующие ampk
PA8783501A1 (es) Derivados de quinaxolina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus
EA200970402A1 (ru) Триазолопиридазиновые модуляторы протеинкиназ
GT200600166A (es) Derivados de cromano y cromeno y usos de los mismos
UY30641A1 (es) Derivados de 2-[1h-pirazol-5-il] y de 2-[2h-pirazol-3-il]tieno[3,2-c]piridinas sustituidas, sus sales farmaceuticamente aceptables y aplicaciones
CR11151A (es) Sales del inhibidor de janus cinasa (r)-3-(4-(7h-pirrolo[2,3-ciclopentilpropanitrilo
AR054277A1 (es) Derivados de piperidin - 4 - il - amida, un proceso para su obtencion, composiciones farmaceuticas que los contienen y su empleo en la fabricacion de medicamentos para el tratamiento de enfermedades asociadas con la modulacion de receptores del subtipo 5 de la sst.
CL2012000708A1 (es) Compuestos derivados de imidazopiridina o imidazopirimidina, inhibidores de pde10a; proceso de preparacion de dichos compuestos; composiciones farmaceuticas; y su uso para el tratamiento terapeutico y/o preventivo de trastornos psicoticos, esquizofrenia, enfermedad de alzheimer, tumores solidos, entre otras enfermedades.
CL2009000957A1 (es) Compuestos derivados de pirrolo[2,3-d]pirimidina; inhibidores de limk2; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos inflamatorios, glaucoma, neurodegeneracion, entre otras.

Legal Events

Date Code Title Description
FB Suspension of granting procedure